Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Martin George Sanda, M.D.

TitleProfessor of Surgery, Emeritus
InstitutionHarvard Medical School
DepartmentEmeritus
AddressBeth Israel Deaconess Med Ctr
Division of Urology, Rabb 4
330 Brookline Ave
Boston MA 02215

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Harden J, Sanda MG, Wei JT, Yarandi HN, Hembroff L, Hardy J, Northouse L. Survivorship after prostate cancer treatment: spouses' quality of life at 36 months. Oncol Nurs Forum. 2013 Nov 1; 40(6):567-73.
    View in: PubMed
  2. Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. Cancer Immunol Immunother. 2013 Dec; 62(12):1831-40.
    View in: PubMed
  3. Gay HA, Michalski JM, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal C, Litwin M, Kuban D, Hembroff L, Chang P, Sanda MG. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology. 2013 Dec; 82(6):1363-9.
    View in: PubMed
  4. Costa DN, Bloch BN, Yao DF, Sanda MG, Ngo L, Genega EM, Pedrosa I, Dewolf WC, Rofsky NM. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies. Magn Reson Imaging. 2013 Jul; 31(6):947-52.
    View in: PubMed
  5. Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM. Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated With Patient-Reported Outcomes: The PROSTQA Experience. Int J Radiat Oncol Biol Phys. 2013 Jul 1; 86(3):546-53.
    View in: PubMed
  6. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013 May 1; 19(9):2442-50.
    View in: PubMed
  7. Harden JK, Sanda MG, Wei JT, Yarandi H, Hembroff L, Hardy J, Northouse LL. Partners' Long-term Appraisal of Their Caregiving Experience, Marital Satisfaction, Sexual Satisfaction, and Quality of Life 2 Years After Prostate Cancer Treatment. Cancer Nurs. 2013 Mar; 36(2):104-13.
    View in: PubMed
  8. Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 1; 119(9):1729-35.
    View in: PubMed
  9. Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ. Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration. J Urol. 2013 May; 189(5):1702-6.
    View in: PubMed
  10. Penson DF, Barocas DA, Fleshner N, Sanda MG, Greenfield S. Outcomes session. Urol Oncol. 2012 Nov; 30(6):952-5.
    View in: PubMed
  11. Kazer MW, Bailey DE, Chipman J, Psutka SP, Hardy J, Hembroff L, Regan M, Dunn RL, Crociani C, Sanda MG. Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. BJU Int. 2013 Mar; 111(3 Pt B):E84-91.
    View in: PubMed
  12. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
  13. Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, Ngo L, Sanda MG, Dewolf WC, Rofsky NM. Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol. 2012 Oct; 22(10):2201-10.
    View in: PubMed
  14. Kim SB, Williams SB, Cheng SC, Sanda MG, Wagner AA. Evaluation of patient-reported quality-of-life outcomes after renal surgery. Urology. 2012 Jun; 79(6):1268-73.
    View in: PubMed
  15. Lu B, Asara JM, Sanda MG, Arredouani MS. The role of the transcription factor SIM2 in prostate cancer. PLoS One. 2011; 6(12):e28837.
    View in: PubMed
  16. Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM. Updating risk prediction tools: a case study in prostate cancer. Biom J. 2012 Jan; 54(1):127-42.
    View in: PubMed
  17. Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. Cancer. 2012 May 15; 118(10):2651-8.
    View in: PubMed
  18. Kasperzyk JL, Shappley WV, Kenfield SA, Mucci LA, Kurth T, Ma J, Stampfer MJ, Sanda MG. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol. 2011 Nov; 186(5):1862-7.
    View in: PubMed
  19. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14.
    View in: PubMed
  20. Kazer MW, Bailey DE, Sanda M, Colberg J, Kelly WK. An Internet intervention for management of uncertainty during active surveillance for prostate cancer. Oncol Nurs Forum. 2011 Sep; 38(5):561-8.
    View in: PubMed
  21. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011 Aug 3; 3(94):94ra72.
    View in: PubMed
  22. Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011 Sep; 186(3):865-72.
    View in: PubMed
  23. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2013 Jul; 31(5):566-71.
    View in: PubMed
  24. Hayn MH, Orom H, Shavers VL, Sanda MG, Glasgow M, Mohler JL, Underwood W. Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer. Cancer. 2011 Oct 15; 117(20):4651-8.
    View in: PubMed
  25. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011 May; 185(5):1650-5.
    View in: PubMed
  26. Kazer MW, Harden J, Burke M, Sanda MG, Hardy J, Bailey DE. The experiences of unpartnered men with prostate cancer: a qualitative analysis. J Cancer Surviv. 2011 Jun; 5(2):132-41.
    View in: PubMed
  27. Sanda MG. Editorial comment. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131. Urology. 2010 Nov; 76(5):1148; author reply 1148-9.
    View in: PubMed
  28. Sanda MG. Urinary obstructive problems exposed but hormonal health-related quality-of-life concerns eschewed in prostate cancer quality-of-life study. J Clin Oncol. 2010 Nov 1; 28(31):4667-8.
    View in: PubMed
  29. Kamo N, Dandapani SV, Miksad RA, Houlihan MJ, Kaplan I, Regan M, Greenfield TK, Sanda MG. Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet. Ann Oncol. 2011 Mar; 22(3):723-9.
    View in: PubMed
  30. Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MA. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with a-galactosylceramide. PLoS One. 2010; 5(6):e11311.
    View in: PubMed
  31. Levinson AW, Ward NT, Sanda MG, Mettee LZ, Wei JT, Su LM, Litwin MS, Pavlovich CP. Comparison of validated instruments measuring sexual function in men. Urology. 2010 Aug; 76(2):380-6.
    View in: PubMed
  32. Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, Escara-Wilke J, Leander KR, Defeo-Jones D, Hwang C, Sanda MG. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate. 2010 Jun 15; 70(9):1002-11.
    View in: PubMed
  33. Dusek J, Sanda M, Loo B, Ray C. Field leaching of pesticides at five test sites in Hawaii: study description and results. Pest Manag Sci. 2010 Jun; 66(6):596-611.
    View in: PubMed
  34. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010 May; 19(5):1193-200.
    View in: PubMed
  35. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010 Nov; 76(5):1245-50.
    View in: PubMed
  36. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22.
    View in: PubMed
  37. Vanek V, Pícha J, Budesínský M, Sanda M, Jirácek J, Holz RC, Hlavácek J. Synthesis of N-succinyl-L,L-diaminopimelic acid mimetics via selective protection. Protein Pept Lett. 2010 Mar; 17(3):405-9.
    View in: PubMed
  38. Sandler HM, Liu PY, Dunn RL, Khan DC, Tropper SE, Sanda MG, Mantz CA. Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. Urology. 2010 May; 75(5):1004-8.
    View in: PubMed
  39. Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol. 2009 Dec; 182(6):2653-8.
    View in: PubMed
  40. Aronovitz JA, Sanda MG. Further perspectives on treating localized prostate cancer. Oncology (Williston Park). 2009 Oct; 23(11):964, 966.
    View in: PubMed
  41. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5794-802.
    View in: PubMed
  42. Shappley WV, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG, Chan JM. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009 Oct 20; 27(30):4980-5.
    View in: PubMed
  43. Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology. 2009 Nov; 74(5):1156-61.
    View in: PubMed
  44. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009 Jul 15; 15(14):4706-11.
    View in: PubMed
  45. Sanda MG. Editorial comment. Nerve sparing during radical prostatectomy is associated with better recovery of urinary continence. Urology. 2009 Jun; 73(6):1340-1; author reply 1341.
    View in: PubMed
  46. Sanda MG, Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA. 2009 May 27; 301(20):2141-51.
    View in: PubMed
  47. Sanda MG. Live longer but not better...yet. Lancet Oncol. 2009 Apr; 10(4):313-4.
    View in: PubMed
  48. Buzek F, Bystricky V, Kadlecova R, Kvitek T, Ondr P, Sanda M, Zajicek A, Zlabek P. Application of two-component model of drainage discharge to nitrate contamination. J Contam Hydrol. 2009 May 12; 106(3-4):99-117.
    View in: PubMed
  49. Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG. A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug Des Devel Ther. 2009; 2:17-24.
    View in: PubMed
  50. McDermott DW, Sanda MG. Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4. Nat Clin Pract Urol. 2009 Mar; 6(3):124-5.
    View in: PubMed
  51. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009 Jan; 8(1):113-7.
    View in: PubMed
  52. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008 Dec; 180(6):2384-8; discussion 2388.
    View in: PubMed
  53. Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate. 2008 Oct 1; 68(14):1517-30.
    View in: PubMed
  54. Hu JC, Hevelone ND, Ferreira MD, Lipsitz SR, Choueiri TK, Sanda MG, Earle CC. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol. 2008 Nov; 180(5):1969-74.
    View in: PubMed
  55. Kershaw TS, Mood DW, Newth G, Ronis DL, Sanda MG, Vaishampayan U, Northouse LL. Longitudinal analysis of a model to predict quality of life in prostate cancer patients and their spouses. Ann Behav Med. 2008 Oct; 36(2):117-28.
    View in: PubMed
  56. Ramachandran N, Anderson KS, Raphael JV, Hainsworth E, Sibani S, Montor WR, Pacek M, Wong J, Eljanne M, Sanda MG, Hu Y, Logvinenko T, Labaer J. Tracking humoral responses using self assembling protein microarrays. Proteomics Clin Appl. 2008 Oct; 2(10-11):1518-27.
    View in: PubMed
  57. Hollenbeck BK, Dunn RL, Wolf JS, Sanda MG, Wood DP, Gilbert SM, Weizer AZ, Montie JE, Wei JT. Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery. Qual Life Res. 2008 Aug; 17(6):915-26.
    View in: PubMed
  58. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008 Aug; 180(2):539-43; discussion 543.
    View in: PubMed
  59. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008 Jun 1; 14(11):3380-5.
    View in: PubMed
  60. Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy. Prostate. 2008 May 15; 68(7):715-27.
    View in: PubMed
  61. Alavi G, Sanda M, Loo B, Green RE, Ray C. Movement of bromacil in a Hawaii soil under pineapple cultivation - a field study. Chemosphere. 2008 May; 72(1):45-52.
    View in: PubMed
  62. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Mar 20; 358(12):1250-61.
    View in: PubMed
  63. Sanda MG, Kasibhatla M. Is androgen suppression therapy associated with early onset of fatal myocardial infarction? Nat Clin Pract Urol. 2008 Apr; 5(4):184-5.
    View in: PubMed
  64. Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. Cancer Immunol Immunother. 2008 Sep; 57(9):1357-65.
    View in: PubMed
  65. Dandapani SV, Sanda MG. Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. Semin Radiat Oncol. 2008 Jan; 18(1):67-72.
    View in: PubMed
  66. Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. Urology. 2008 Jan; 71(1):47-51.
    View in: PubMed
  67. Northouse LL, Mood DW, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC, Sanda MG, Kershaw T. Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol. 2007 Sep 20; 25(27):4171-7.
    View in: PubMed
  68. Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. Urology. 2006 Dec; 68(6):1224-9.
    View in: PubMed
  69. Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA. 2006 Nov 15; 296(19):2316-7.
    View in: PubMed
  70. Montgomery JS, Gayed BA, Hollenbeck BK, Daignault S, Sanda MG, Montie JE, Wei JT. Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. J Urol. 2006 Jul; 176(1):257-61; discussion 261-2.
    View in: PubMed
  71. Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin PW, Sanda MG. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology. 2006 Jul; 68(1):166-71.
    View in: PubMed
  72. Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA. Prognostic factors in lymph node-positive prostate cancer. Urology. 2006 May; 67(5):1016-21.
    View in: PubMed
  73. Takegami M, Suzukamo Y, Sanda MG, Kamoto T, Namiki S, Arai Y, Ogawa O, Fukuhara S, Kakehi Y. [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC)]. Nihon Hinyokika Gakkai Zasshi. 2005 Nov; 96(7):657-69.
    View in: PubMed
  74. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. N Engl J Med. 2005 Sep 22; 353(12):1224-35.
    View in: PubMed
  75. Bradley SV, Oravecz-Wilson KI, Bougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Corradetti MN, Chinnaiyan AM, Sanda MG, Ross TS. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res. 2005 May 15; 65(10):4126-33.
    View in: PubMed
  76. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin WP, Wei JT. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005 Apr 20; 23(12):2772-80.
    View in: PubMed
  77. Shah NL, Sanda M. Health-related quality of life in treatment for prostate cancer: looking beyond survival. Support Cancer Ther. 2004 Jul 1; 1(4):230-6.
    View in: PubMed
  78. Dash A, Dunn RL, Resh J, Wei JT, Montie JE, Sanda MG. Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. Urology. 2004 Jul; 64(1):117-22.
    View in: PubMed
  79. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst. 2004 Jun 2; 96(11):834-43.
    View in: PubMed
  80. Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG. Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. Curr Urol Rep. 2004 Jun; 5(3):212-9.
    View in: PubMed
  81. Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. Urology. 2004 May; 63(5):946-50.
    View in: PubMed
  82. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004 Apr; 171(4):1504-7.
    View in: PubMed
  83. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA, Chinnaiyan AM. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol. 2004 Mar; 164(3):787-93.
    View in: PubMed
  84. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004 Feb 1; 64(3):825-9.
    View in: PubMed
  85. Underwood W, Wei J, Rubin MA, Montie JE, Resh J, Sanda MG. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. Urol Oncol. 2004 Jan-Feb; 22(1):20-4.
    View in: PubMed
  86. Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA, Day ML. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6447-52.
    View in: PubMed
  87. Tsien C, Griffith KA, Sandler HM, McLaughlin P, Sanda MG, Montie J, Reddy S, Hayman JA. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology. 2003 Jul; 62(1):93-8.
    View in: PubMed
  88. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst. 2003 May 7; 95(9):661-8.
    View in: PubMed
  89. Nelson CP, Dunn RL, Wei JT, Rubin MA, Montie JE, Sanda MG. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. Urol Oncol. 2003 May-Jun; 21(3):213-8.
    View in: PubMed
  90. Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol. 2003 Apr; 169(4):1453-7.
    View in: PubMed
  91. Miller DC, Litwin MS, Sanda MG, Montie JE, Dunn RL, Resh J, Sandler H, Wei JT. Use of quality indicators to evaluate the care of patients with localized prostate carcinoma. Cancer. 2003 Mar 15; 97(6):1428-35.
    View in: PubMed
  92. Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate. 2002 Nov 1; 53(3):183-91.
    View in: PubMed
  93. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002 Oct 10; 419(6907):624-9.
    View in: PubMed
  94. Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol. 2002 Oct; 168(4 Pt 1):1315-25.
    View in: PubMed
  95. Dash A, Sanda MG, Yu M, Taylor JM, Fecko A, Rubin MA. Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer. Urology. 2002 Aug; 60(2):276-80.
    View in: PubMed
  96. Rao DS, Hyun TS, Kumar PD, Mizukami IF, Rubin MA, Lucas PC, Sanda MG, Ross TS. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest. 2002 Aug; 110(3):351-60.
    View in: PubMed
  97. Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology. 2002 May; 59(5):740-5; discussion 745-6.
    View in: PubMed
  98. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002 Apr 3; 287(13):1662-70.
    View in: PubMed
  99. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG. Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology. 2002 Apr; 59(4):480-4.
    View in: PubMed
  100. Litzenberg D, Dawson LA, Sandler H, Sanda MG, McShan DL, Ten Haken RK, Lam KL, Brock KK, Balter JM. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys. 2002 Mar 1; 52(3):699-703.
    View in: PubMed
  101. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, Sanda MG. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002 Jan 15; 20(2):557-66.
    View in: PubMed
  102. Kielb S, Dunn RL, Rashid MG, Murray S, Sanda MG, Montie JE, Wei JT. Assessment of early continence recovery after radical prostatectomy: patient reported symptoms and impairment. J Urol. 2001 Sep; 166(3):958-61.
    View in: PubMed
  103. Kielb SJ, Shah NL, Rubin MA, Sanda MG. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol. 2001 Aug; 166(2):482-7.
    View in: PubMed
  104. Taj MM, Tawil RJ, Engstrom LD, Zeng Z, Hwang C, Sanda MG, Wechsler DS. Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. Prostate. 2001 May 15; 47(3):194-204.
    View in: PubMed
  105. Imperiale MJ, Pass HI, Sanda MG. Prospects for an SV40 vaccine. Semin Cancer Biol. 2001 Feb; 11(1):81-5.
    View in: PubMed
  106. Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, Day ML. Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res. 2001 Jan 15; 61(2):489-92.
    View in: PubMed
  107. Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, Hammond E, Hanks G, Heydon KH, Kaufman DS, Lee WR, Michalski J, Mydlo J, Pisansky T, Pollack A, Porterfield H, Rifkin M, Roach M, Sanda M, True L, Vijayakumar S, Winter KA, Zeitman A. Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):28-38.
    View in: PubMed
  108. Rubin MA, Mucci NR, Manley S, Sanda M, Cushenberry E, Strawderman M, Montie JE, Bassily NH. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively? J Urol. 2001 Jan; 165(1):114-8.
    View in: PubMed
  109. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000 Dec 20; 56(6):899-905.
    View in: PubMed
  110. Shah R, Bassily N, Wei J, Mucci NR, Montie JE, Sanda MG, Rubin MA. Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. Urology. 2000 Nov 1; 56(5):721-5.
    View in: PubMed
  111. Wei JT, Dunn RL, Marcovich R, Montie JE, Sanda MG. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol. 2000 Sep; 164(3 Pt 1):744-8.
    View in: PubMed
  112. Dawson LA, Litzenberg DW, Brock KK, Sanda M, Sullivan M, Sandler HM, Balter JM. A comparison of ventilatory prostate movement in four treatment positions. Int J Radiat Oncol Biol Phys. 2000 Sep 1; 48(2):319-23.
    View in: PubMed
  113. Paulus HE, Di Primeo D, Sanda M, Lynch JM, Schwartz BA, Sharp JT, Genant HK, Weissman BN. Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol. 2000 Jul; 27(7):1632-7.
    View in: PubMed
  114. Marcovich R, Wojno KJ, Wei JT, Rubin MA, Montie JE, Sanda MG. Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology. 2000 Jun; 55(6):904-8.
    View in: PubMed
  115. Charles LG, Xie YC, Restifo NP, Roessler B, Sanda MG. Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. World J Urol. 2000 Apr; 18(2):136-42.
    View in: PubMed
  116. Rubin MA, Bassily N, Sanda M, Montie J, Strawderman MS, Wojno K. Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am J Surg Pathol. 2000 Feb; 24(2):183-9.
    View in: PubMed
  117. Tchetgen MB, Sanda MG, Montie JE, Faerber GJ. Collagen injection for the treatment of incontinence after cystectomy and orthotopic neobladder reconstruction in women. J Urol. 2000 Jan; 163(1):212-4.
    View in: PubMed
  118. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol. 2000; 46 Suppl:S67-72.
    View in: PubMed
  119. Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, Sanda MG. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology. 1999 Dec; 54(6):1112-9.
    View in: PubMed
  120. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999 Oct 15; 59(20):5160-8.
    View in: PubMed
  121. Hwang C, Sanda MG. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Curr Opin Mol Ther. 1999 Aug; 1(4):471-9.
    View in: PubMed
  122. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999 Feb; 53(2):260-6.
    View in: PubMed
  123. Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Mulé JJ, Imperiale MJ, Restifo NP, Sanda MG. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst. 1999 Jan 20; 91(2):169-75.
    View in: PubMed
  124. Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Greenberg NM, Zeng Z, Sanda MG. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol. 1998 Oct; 160(4):1500-5.
    View in: PubMed
  125. Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, Stoner E, Walsh PC. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol. 1997 Mar; 157(3):876-9.
    View in: PubMed
  126. Sanda MG. Biological principles and clinical development of prostate cancer gene therapy. Semin Urol Oncol. 1997 Feb; 15(1):43-55.
    View in: PubMed
  127. Doehring CB, Sanda MG, Partin AW, Sauvageot J, Juo H, Beaty TH, Epstein JI, Hill G, Walsh PC. Histopathologic characterization of hereditary benign prostatic hyperplasia. Urology. 1996 Oct; 48(4):650-3.
    View in: PubMed
  128. Sanda MG, Jeffs RD, Gearhart JP. Evolution of outcomes with the ileal hydraulic valve continent diversion: reevaluation of the Benchekroun catheterizable stoma. World J Urol. 1996; 14(2):108-11.
    View in: PubMed
  129. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, Simons JW. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995 May; 45(5):831-8.
    View in: PubMed
  130. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst. 1995 Feb 15; 87(4):280-5.
    View in: PubMed
  131. Moore RG, Demaree RD, Sanda MG, Kavoussi LR. Retroperitoneoscopy: effects of insufflation media on surrounding tissue during balloon rupture. J Endourol. 1995 Feb; 9(1):67-71.
    View in: PubMed
  132. Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology. 1994 Nov; 44(5):646-50.
    View in: PubMed
  133. Sanda MG, Simons JW. Gene therapy for urologic cancer. Urology. 1994 Oct; 44(4):617-24.
    View in: PubMed
  134. Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J Urol. 1994 Jul; 152(1):115-9.
    View in: PubMed
  135. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994 Mar; 151(3):622-8.
    View in: PubMed
  136. Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW, et al. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J Natl Cancer Inst. 1994 Jan 5; 86(1):39-45.
    View in: PubMed
  137. Hayashi J, Hidaka N, Sanda M, Ohashi N, Yajima Y, Furukawa Y, Kato M. [A effective combination preoperative intraarterial infusion chemotherapy and irradiation for advanced sigmoid colon cancer with bladder invasion]. Nihon Shokakibyo Gakkai Zasshi. 1992 Nov; 89(11):2714-8.
    View in: PubMed
  138. Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Belfort R, de Smet MD, Schwartzentruber DJ, White DE, Lotze MT, et al. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. J Clin Oncol. 1992 Oct; 10(10):1643-9.
    View in: PubMed
  139. Sanda MG, Bolton E, Mulé JJ, Rosenberg SA. In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. J Immunother (1991). 1992 Aug; 12(2):132-7.
    View in: PubMed
  140. Barth RJ, Mulé JJ, Asher AL, Sanda MG, Rosenberg SA. Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor. J Immunol Methods. 1991 Jul 5; 140(2):269-79.
    View in: PubMed
  141. Lanza F, Rack MF, Lynn M, Wolf J, Sanda M. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol. 1987 Apr; 14(2):338-41.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Sanda's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_